● Recruiting

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Condition: Advanced Solid Tumor · Homologous Recombination Deficiency · HRR Deficiency · Sponsor: Eisbach Bio GmbH

PhasePhase 1/Phase 2

Planned participants144

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

This description comes directly from the study's public registry record.

Talk to the study team

Adrian Schomburg · +49 17621046886 · adrian@eisbach.bio

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06525298